On May 2, 2025, Biogen (BIIB, Financial) received an updated analyst rating from Needham. Analyst Ami Fadia has reiterated a "Hold" rating on the stock. There were no changes to the price target, as no specific target was provided in the latest update.
The "Hold" rating indicates that the analyst believes the stock is expected to perform in line with the market or sector over the medium term. This assessment suggests that investors may not see significant upside or downside in the stock in the near future based on the current market conditions.
Investors and market participants can find this latest update important for their decision-making process regarding Biogen (BIIB, Financial). It is essential to follow ongoing updates and reports from various analysts to get a comprehensive view of stock performance expectations.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 29 analysts, the average target price for Biogen Inc (BIIB, Financial) is $180.15 with a high estimate of $300.00 and a low estimate of $115.00. The average target implies an upside of 48.97% from the current price of $120.93. More detailed estimate data can be found on the Biogen Inc (BIIB) Forecast page.
Based on the consensus recommendation from 37 brokerage firms, Biogen Inc's (BIIB, Financial) average brokerage recommendation is currently 2.5, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Biogen Inc (BIIB, Financial) in one year is $211.68, suggesting a upside of 75.04% from the current price of $120.93. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Biogen Inc (BIIB) Summary page.
